Advertisement
Amazon
Amazon

Gene Therapy...

Since 1998, when 18-year-old Jesse Gelsinger died in a clinical trial at the University of Pennsylvania, the news on gene therapy hasn't gotten much better.

May 9, 2005

<p/>

David Mack/Photo Researchers, Inc.

Since 1998, when 18-year-old Jesse Gelsinger died in a clinical trial at the University of Pennsylvania, the news on gene therapy hasn't gotten much better. In a recent trial, three children developed leukemia almost certainly brought on by their treatment for X-linked severe combined immunodeficiency (X-SCID). So it's no surprise that there's some trepidation on the part of investors when it comes to companies exploring new gene-altering techniques – the subject of the opening piece of our special feature section on gene therapy.

Still, it's an inescapable fact that gene therapy saved the lives of other children in that same X-SCID trial. Those kinds of results are encouraging for people like Carl June, director of translational research at the Abramson Cancer Center at the University of Pennsylvania, who writes on why cancer gene therapy will be both a medical and financial success. Finally, this issue's Hot Papers recount the discovery of the misdirected transgene responsible for leukemia in two of the affected children and the warning signs that indicate that some retroviral vectors are prone to cause such problems. There's clearly a long road ahead for gene therapy, but it's certainly not the dead end it may have seemed in the past.

Advertisement
EMD Millipore
EMD Millipore

Popular Now

  1. The Zombie Literature
    Features The Zombie Literature

    Retractions are on the rise. But reams of flawed research papers persist in the scientific literature. Is it time to change the way papers are published?

  2. First Data from Anti-Aging Gene Therapy
  3. Locating Language within the Brain
  4. The Two Faces of Fish Oil
    Notebook The Two Faces of Fish Oil

    The discovery of a tumor-protecting role for a fatty acid found in fish oil has sparked debate about the product’s safety.

Advertisement
Diagenode
Diagenode
Advertisement
RayBioTech